GlassScriptPhysician profile
Mohir Hedeshian
NPI 1871704049
$3,198.36
in general payments reported to CMS, 2019-2025
34 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $124 · 2021: $23.81 · 2022: $417 · 2023: $1,338 · 2024: $355 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898 · Travel and Lodging: $19.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,897.77 |
| Travel and Lodging | $19.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $478.45 | 2019-2024 | Da Vinci Surgical System |
| Actelion Pharmaceuticals US, INC. | $327.77 | 2023-2024 | Uptravi, Opsumit, Bosentan |
| Bayer Healthcare Pharmaceuticals INC. | $282.49 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $272.82 | 2019-2025 | Keytruda, Lynparza, Bridion |
| E.R. Squibb & Sons, L.L.C. | $236.88 | 2019-2023 | Opdivo |
| Seagen INC. | $180.12 | 2019-2023 | Padcev |
| Eisai INC. | $172.07 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $133.25 | 2019-2024 | Tagrisso, Imfinzi |
| Exelixis INC. | $118.58 | 2022-2023 | Cabometyx |
| Janssen Pharmaceuticals, INC | $105.06 | 2019 | |
| Atricure, INC. | $91.01 | 2024-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Incyte Corporation | $65.11 | 2019-2022 | |
| Gilead Sciences, INC. | $55.48 | 2022-2023 | |
| Abbvie INC. | $54.57 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.00 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $52.52 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Pharmacyclics LLC, An Abbvie Company | $49.79 | 2019-2023 | Imbruvica |
| Genzyme Corporation | $47.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.95 | 2019-2025 | Ninlaro |
| Regeneron Healthcare Solutions, INC. | $43.55 | 2022-2024 | Libtayo |
| Covidien LP | $37.95 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.16 | 2019 | |
| Glaxosmithkline, LLC. | $32.56 | 2023 | Nucala |
| Pfizer INC. | $31.53 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.98 | 2019 | |
| Mirati Therapeutics, INC. | $24.30 | 2024 | Krazati |
| Myovant Sciences INC. | $24.09 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.81 | 2021 | |
| Celgene Corporation | $22.82 | 2019 | |
| Biocon Biologics INC | $19.98 | 2024 | Fulphila |
| Covis Pharma Gmbh | $17.08 | 2022 | |
| Globus Medical, INC. | $13.78 | 2025 | Mars, Lateralalif |
| Medtronic, INC. | $13.65 | 2024 | Endo Gia Ultra |
| Medtronic Vascular, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohir Hedeshian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.